- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Conditions for Administering Bispecific Therapy
Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.
EP: 1.Conditions for Administering Bispecific Therapy
EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics
EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration
EP: 4.Pain Points In Bispecific Operationalization
EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
EP: 6.Optimizing Bispecific Use Through EMR Utilization
EP: 7.Best Practices For Uptake and Use of Bispecific Therapy
EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy
EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions
EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies
EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care
EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies
EP: 13.Managed Care Considerations Within Bispecific Landscape
EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies
EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy
EP: 16.Bispecific Therapies: Current and Future Considerations
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
The video discusses considerations for operationalizing bispecific monoclonal antibodies in cancer care. It highlights the importance of having protocols in place for patient monitoring, transition of care, risk evaluation and mitigation strategies programs, management of adverse events like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term toxicity monitoring. Key factors include setting patient eligibility criteria, caregiver reliability for adherence, transportation to handle severe adverse effects, and financial considerations for insurance authorizations. As these are continuous therapies, extensive plans must be made to support patients across the entirety of their treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More
